MediPharm Labs Corp.
MEDIF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.08 | 0.03 | 0.01 | 0.02 |
| FCF Yield | -20.70% | -52.33% | -92.74% | -30.35% |
| EV / EBITDA | -1.72 | -0.73 | 0.21 | -0.32 |
| Quality | ||||
| ROIC | -24.81% | -32.32% | -52.13% | -58.63% |
| Gross Margin | 30.52% | 17.71% | -8.65% | -70.22% |
| Cash Conversion Ratio | 0.45 | 0.90 | 0.54 | 0.24 |
| Growth | ||||
| Revenue 3-Year CAGR | 23.80% | 15.05% | -15.00% | -44.82% |
| Free Cash Flow Growth | 59.01% | 27.75% | -20.98% | 69.09% |
| Safety | ||||
| Net Debt / EBITDA | 1.50 | 1.50 | 0.92 | 0.88 |
| Interest Coverage | -18.77 | -50.01 | -952.68 | -4.66 |
| Efficiency | ||||
| Inventory Turnover | 3.35 | 2.75 | 3.09 | 3.37 |
| Cash Conversion Cycle | 121.34 | 168.83 | 278.98 | 363.28 |